Nis Halland

This inventor holds 15 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 16 EPO patents. Top assignees: Sanofi, Sanofi-Aventis, Sanofi-Aventis Recherche & Développement. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nis Halland. Retrieved from https://idiyas.com/inventor/nis-halland

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 46.7

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 16 (Patent Applications = 18)

Average Co-Inventor Count = 7.0

ph-index = 3

Forward Citations = 60(Granted Patents)

Location History:

Bad Soden, DE (2011)
Frankfurt-am-Main, DE (2012 - 2019)

Company Filing History:

Sanofi-Aventis Recherche & Développement

patents

Years Active: 2011-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679878 - CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY (2026-07-14),

2. 10392366 - Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2019-08-27),

3. 9908868 - Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2018-03-06),

4. 9896434 - Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2018-02-20),

5. 9758520 - Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2017-09-12),

6. 9718825 - N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals (2017-08-01),

7. 9221828 - N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]sulfonamides as pharmaceuticals (2015-12-29),

8. 9174993 - N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals (2015-11-03),

9. 8735586 - Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles (2014-05-27),

10. 8487109 - Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates (2013-07-16),

11. 8420812 - Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates (2013-04-16),

12. 8389764 - Urea and sulfamide derivatives as inhibitors of TAFIa (2013-03-05),

13. 8283476 - Transition metal catalyzed synthesis of 2H-indazoles (2012-10-09),

14. 8188282 - Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles (2012-05-29),

15. 8026375 - Transition metal catalyzed synthesis of N-aminoindoles (2011-09-27),

Title: The Innovative Journey of Nis Halland

Introduction: Nis Halland, a visionary inventor hailing from Frankfurt am Main, DE, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Nis Halland's latest patents include a cutting-edge AI-powered healthcare device for remote patient monitoring and a revolutionary renewable energy system designed for urban environments.

Career Highlights: With over two decades of experience in the tech industry, Nis Halland has a proven track record of turning innovative ideas into successful products. He has held key roles in several tech companies, leading research and development teams to create cutting-edge solutions.

Collaborations: Throughout his career, Nis Halland has collaborated with top researchers, engineers, and designers from around the globe. His collaborative projects have resulted in patents that have pushed the boundaries of technology and improved the lives of many.

Conclusion: Nis Halland's passion for innovation and his relentless drive to create a positive impact on society make him a true pioneer in the world of technology. His inventive spirit continues to inspire the next generation of inventors and innovators.

Profile summary based on public USPTO records.